Join Indica Labs for Next Week’s Webinar
recent articles
Visiopharm A/S, a global leader in Quantitative Digital Pathology, announced today release of its novel CE-IVD module HER2-CONNECT for assessing Her2 status in breast cancer patients Without any requirements for manual outlining of tumor...
According to the The Pathology Blawg this matter I first talked about in October 2010 has been settled by Mayo Clinic for $1.26 million. Suit Alleges Mayo Overbilled for Pathology Services, Justice Department Joins Suit (Originally posted...
Courtesy of DarkDaily: 23andMe executives want the credibility that FDA clearance provides for its DNA tests and declared their intent to eventually support more clinical laboratory test applicationsOffering genetic tests directly...
August 3, 2012 | By Susan D. Hall FierceHealthIT Researchers claimed success using an SAS-based natural-language processing (NLP) tool to detect breast and prostate cancers from pathology reports, according to...
Came across this as a CAP Today commercial message from Cleveland Clinic entitled "Diagnose Patients Faster with Cleveland Clinic Labs" eIHC solutions similar to Clarient it appears with Ventana images and Aperio scanning...
A new analysis has found that doing away with PSA (prostate specific antigen) testing for prostate cancer would likely cause three times as many men to develop advanced disease that has spread to other parts of the body before being...
